Analysis and Commentary STEVEN GROSSMAN 11/1/24 Analysis and Commentary STEVEN GROSSMAN 11/1/24 Presidential Transition: Coming Soon to the FDA Read More Analysis and Commentary STEVEN GROSSMAN 10/18/24 Analysis and Commentary STEVEN GROSSMAN 10/18/24 Steven Is Moving On to New FDA Challenges Read More Analysis and Commentary STEVEN GROSSMAN 10/4/24 Analysis and Commentary STEVEN GROSSMAN 10/4/24 We Got the FY 25 CR Story Right, What’s Next? Part 2 Read More Analysis and Commentary STEVEN GROSSMAN 9/27/24 Analysis and Commentary STEVEN GROSSMAN 9/27/24 We Got the FY 25 CR Story Right, What’s Next? Read More Analysis and Commentary STEVEN GROSSMAN 9/20/24 Analysis and Commentary STEVEN GROSSMAN 9/20/24 Remembrance of October 1’s Past Read More Analysis and Commentary STEVEN GROSSMAN 9/13/24 Analysis and Commentary STEVEN GROSSMAN 9/13/24 The Pentagon is FDA’s Ally, Really! Read More Analysis and Commentary STEVEN GROSSMAN 9/6/24 Analysis and Commentary STEVEN GROSSMAN 9/6/24 Establishing Reasonable Expectations for the First FY 25 CR Read More Analysis and Commentary STEVEN GROSSMAN 8/30/24 Analysis and Commentary STEVEN GROSSMAN 8/30/24 Q&A: Bumpy September Ride for Government Funding Read More Analysis and Commentary STEVEN GROSSMAN 8/2/24 Analysis and Commentary STEVEN GROSSMAN 8/2/24 September Focus on Continuing Resolution Likely to Mask Broader Budget Discussions Read More Analysis and Commentary STEVEN GROSSMAN 7/26/24 Analysis and Commentary STEVEN GROSSMAN 7/26/24 Hurry Up then Wait = Focus Shifts to CR in September Read More Analysis and Commentary STEVEN GROSSMAN 7/19/24 Analysis and Commentary STEVEN GROSSMAN 7/19/24 Are We There Yet? Appropriations Q&A for Mid-July 2024 Read More Analysis and Commentary STEVEN GROSSMAN 7/12/24 Analysis and Commentary STEVEN GROSSMAN 7/12/24 The Alliance Expresses Concern/Disappointment with House and Senate Mark-ups Read More Analysis and Commentary STEVEN GROSSMAN 7/8/24 Analysis and Commentary STEVEN GROSSMAN 7/8/24 Past Analyses Provide Context for House and Senate Action on Ag-FDA Funding (Special Edition) Read More Analysis and Commentary STEVEN GROSSMAN 6/21/24 Analysis and Commentary STEVEN GROSSMAN 6/21/24 Two Pathways for Saving FDA’s FY 25 Budget Read More Analysis and Commentary STEVEN GROSSMAN 6/14/24 Analysis and Commentary STEVEN GROSSMAN 6/14/24 The Past is Prologue, But Subcommittee Bills May Not Be Read More Analysis and Commentary STEVEN GROSSMAN 6/7/24 Analysis and Commentary STEVEN GROSSMAN 6/7/24 What the FY 24 Appropriations Cycle Tells Us About FY 25 Read More Analysis and Commentary STEVEN GROSSMAN 5/31/24 Analysis and Commentary STEVEN GROSSMAN 5/31/24 “Hurry Up and Wait” and Other Appropriations Questions Read More Analysis and Commentary STEVEN GROSSMAN 5/17/24 Analysis and Commentary STEVEN GROSSMAN 5/17/24 Three Things We Heard in Senate-side Hill Meetings Read More Analysis and Commentary STEVEN GROSSMAN 5/10/24 Analysis and Commentary STEVEN GROSSMAN 5/10/24 Three Things We Heard in House-side Hill Meetings Read More Analysis and Commentary STEVEN GROSSMAN 5/3/24 Analysis and Commentary STEVEN GROSSMAN 5/3/24 Q&A on the Urgent Need for FDA Advocacy Read More Older Posts
Analysis and Commentary STEVEN GROSSMAN 11/1/24 Analysis and Commentary STEVEN GROSSMAN 11/1/24 Presidential Transition: Coming Soon to the FDA Read More
Analysis and Commentary STEVEN GROSSMAN 10/18/24 Analysis and Commentary STEVEN GROSSMAN 10/18/24 Steven Is Moving On to New FDA Challenges Read More
Analysis and Commentary STEVEN GROSSMAN 10/4/24 Analysis and Commentary STEVEN GROSSMAN 10/4/24 We Got the FY 25 CR Story Right, What’s Next? Part 2 Read More
Analysis and Commentary STEVEN GROSSMAN 9/27/24 Analysis and Commentary STEVEN GROSSMAN 9/27/24 We Got the FY 25 CR Story Right, What’s Next? Read More
Analysis and Commentary STEVEN GROSSMAN 9/20/24 Analysis and Commentary STEVEN GROSSMAN 9/20/24 Remembrance of October 1’s Past Read More
Analysis and Commentary STEVEN GROSSMAN 9/13/24 Analysis and Commentary STEVEN GROSSMAN 9/13/24 The Pentagon is FDA’s Ally, Really! Read More
Analysis and Commentary STEVEN GROSSMAN 9/6/24 Analysis and Commentary STEVEN GROSSMAN 9/6/24 Establishing Reasonable Expectations for the First FY 25 CR Read More
Analysis and Commentary STEVEN GROSSMAN 8/30/24 Analysis and Commentary STEVEN GROSSMAN 8/30/24 Q&A: Bumpy September Ride for Government Funding Read More
Analysis and Commentary STEVEN GROSSMAN 8/2/24 Analysis and Commentary STEVEN GROSSMAN 8/2/24 September Focus on Continuing Resolution Likely to Mask Broader Budget Discussions Read More
Analysis and Commentary STEVEN GROSSMAN 7/26/24 Analysis and Commentary STEVEN GROSSMAN 7/26/24 Hurry Up then Wait = Focus Shifts to CR in September Read More
Analysis and Commentary STEVEN GROSSMAN 7/19/24 Analysis and Commentary STEVEN GROSSMAN 7/19/24 Are We There Yet? Appropriations Q&A for Mid-July 2024 Read More
Analysis and Commentary STEVEN GROSSMAN 7/12/24 Analysis and Commentary STEVEN GROSSMAN 7/12/24 The Alliance Expresses Concern/Disappointment with House and Senate Mark-ups Read More
Analysis and Commentary STEVEN GROSSMAN 7/8/24 Analysis and Commentary STEVEN GROSSMAN 7/8/24 Past Analyses Provide Context for House and Senate Action on Ag-FDA Funding (Special Edition) Read More
Analysis and Commentary STEVEN GROSSMAN 6/21/24 Analysis and Commentary STEVEN GROSSMAN 6/21/24 Two Pathways for Saving FDA’s FY 25 Budget Read More
Analysis and Commentary STEVEN GROSSMAN 6/14/24 Analysis and Commentary STEVEN GROSSMAN 6/14/24 The Past is Prologue, But Subcommittee Bills May Not Be Read More
Analysis and Commentary STEVEN GROSSMAN 6/7/24 Analysis and Commentary STEVEN GROSSMAN 6/7/24 What the FY 24 Appropriations Cycle Tells Us About FY 25 Read More
Analysis and Commentary STEVEN GROSSMAN 5/31/24 Analysis and Commentary STEVEN GROSSMAN 5/31/24 “Hurry Up and Wait” and Other Appropriations Questions Read More
Analysis and Commentary STEVEN GROSSMAN 5/17/24 Analysis and Commentary STEVEN GROSSMAN 5/17/24 Three Things We Heard in Senate-side Hill Meetings Read More
Analysis and Commentary STEVEN GROSSMAN 5/10/24 Analysis and Commentary STEVEN GROSSMAN 5/10/24 Three Things We Heard in House-side Hill Meetings Read More
Analysis and Commentary STEVEN GROSSMAN 5/3/24 Analysis and Commentary STEVEN GROSSMAN 5/3/24 Q&A on the Urgent Need for FDA Advocacy Read More
